Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.
Kuwahara
Reiichiro
R
Second Department of Medicine, Kurume University School of Medicine, Kurume, Japan. ray@med.kurume-u.ac.jp
Kumashiro
Ryukichi
R
Inoue
Hiroto
H
Tanabe
Ryo
R
Tanaka
Eisuke
E
Hino
Teruko
T
Ide
Tatsuya
T
Koga
Yuriko
Y
Sata
Michio
M
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000378:metabolism; D004351:Drug Resistance; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D017093:Liver Failure / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D019233:Retreatment; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D000225:Adenine; C106812:adefovir dipivoxil